LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akcijų sąrašas・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Uždarymo kaina

27.66 -1.85

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.28

Max

28.04

Pagrindiniai rodikliai
By Trading Economics
Pajamos	43M 13M
Pardavimai	29M 107M
Pelnas, tenkantis vienai akcijai	0.25
Pelno marža	12.139
Darbuotojai	524
EBITDA	16M 8.2M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+130.22% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	32M 1.5B
Ankstesnė atidarymo kaina	29.51
Ankstesnė uždarymo kaina	27.66

Immunocore Holdings PLC ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-08 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026-06-08 15:41; UTC

Pagrindinės rinkos jėgos

American Battery Shares Jump on Energy Department Victory

2026-06-08 23:46; UTC

Rinkos pokalbiai

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026-06-08 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026-06-08 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Agrees to Buy m3ter

2026-06-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-08 19:22; UTC

Rinkos pokalbiai

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026-06-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026-06-08 18:17; UTC

Rinkos pokalbiai

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026-06-08 17:32; UTC

Rinkos pokalbiai

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-08 16:55; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026-06-08 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026-06-08 16:40; UTC

Rinkos pokalbiai

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026-06-08 16:31; UTC

Rinkos pokalbiai

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026-06-08 16:27; UTC

Rinkos pokalbiai

Mexican Inflation Seen Easing in May -- Market Talk

2026-06-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-08 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Orange Bought Stake From Lorca

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Acquires 100% Ownership of MasOrange

2026-06-08 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 15:58; UTC

Rinkos pokalbiai

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026-06-08 15:55; UTC

Rinkos pokalbiai

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026-06-08 15:41; UTC

Rinkos pokalbiai

Gold Falls Below 200-Day Moving Average -- Market Talk

Akcijų palyginimas

Kainos pokytis

Immunocore Holdings PLC ADR Prognozė

Kainos tikslas

By TipRanks

130.22% į viršų

12 mėnesių prognozė

Vidutinis 65.13 USD 130.22%

Aukščiausias 100 USD

Žemiausias 33 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Immunocore Holdings PLC ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Immunocore Holdings PLC ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.